Evidence map›Paper›PMID 26775178›Full record

ArticleExperimental neurology2016

Macrophage-mediated inflammation and glial response in the skeletal muscle of a rat model of familial amyotrophic lateral sclerosis (ALS).

Jonathan M Van Dyke, Ivy M Smit-Oistad, Corey Macrander, Dan Krakora, Michael G Meyer, Masatoshi Suzuki

Abstract read
In one paragraph

Article in Experimental neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 92 citations in OpenAlex.

  1. Review
  2. Article
  3. Review of the Pathology of Muscle in Amyotrophic Lateral Sclerosis.International journal of molecular sciences · 2026
    Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Jonathan M Van DykeDepartment of Comparative Biosciences and The Stem Cell and Regenerative Medicine Center, University of Wisconsin-Madison, Madison, WI, USA.
Ivy M Smit-OistadDepartment of Comparative Biosciences and The Stem Cell and Regenerative Medicine Center, University of Wisconsin-Madison, Madison, WI, USA.
Corey MacranderDepartment of Comparative Biosciences and The Stem Cell and Regenerative Medicine Center, University of Wisconsin-Madison, Madison, WI, USA.
Dan KrakoraDepartment of Comparative Biosciences and The Stem Cell and Regenerative Medicine Center, University of Wisconsin-Madison, Madison, WI, USA.
Michael G MeyerDepartment of Comparative Biosciences and The Stem Cell and Regenerative Medicine Center, University of Wisconsin-Madison, Madison, WI, USA.
Masatoshi SuzukiDepartment of Comparative Biosciences and The Stem Cell and Regenerative Medicine Center, University of Wisconsin-Madison, Madison, WI, USA. Electronic address: masatoshi.suzuki@wisc.edu.
University of Wisconsin–Madison · US

Funding

Muscle stem cells: New ALS growth factor therapy and disease modelR01NS091540 · NINDS · UNIVERSITY OF WISCONSIN-MADISON · PI SUZUKI, MASATOSHI · 2015 to 2019
$1.7M
Stem cell therapy targeting skeletal muscles for ALSR21NS061049 · NINDS · UNIVERSITY OF WISCONSIN-MADISON · PI SUZUKI, MASATOSHI · 2008 to 2009
$357k
NINDS NIH HHS R01 NS091540NINDS NIH HHS R01NS091540NINDS NIH HHS R21 NS061049
6 · The paper itself

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by progressive motor dysfunction and loss of large motor neurons in the spinal cord and brain stem. While much research has focused on mechanisms of motor neuron cell death in the spinal cord, degenerative processes in skeletal muscle and neuromuscular junctions (NMJs) are also observed early in disease development. Although recent studies support the potential therapeutic benefits of targeting the skeletal muscle in ALS, relatively little is known about inflammation and glial responses in skeletal muscle and near NMJs, or how these responses contribute to motor neuron survival, neuromuscular innervation, or motor dysfunction in ALS. We recently showed that human mesenchymal stem cells modified to release glial cell line-derived neurotrophic factor (hMSC-GDNF) extend survival and protect NMJs and motor neurons in SOD1(G93A) rats when delivered to limb muscles. In this study, we evaluate inflammatory and glial responses near NMJs in the limb muscle collected from a rat model of familial ALS (SOD1(G93A) transgenic rats) during disease progression and following hMSC-GDNF transplantation. Muscle samples were collected from pre-symptomatic, symptomatic, and end-stage animals. A significant increase in the expression of microglial inflammatory markers (CD11b and CD68) occurred in the skeletal muscle of symptomatic and end-stage SOD1(G93A) rats. Inflammation was confirmed by ELISA for inflammatory cytokines interleukin-1 β (IL-1β) and tumor necrosis factor-α (TNF-α) in muscle homogenates of SOD1(G93A) rats. Next, we observed active glial responses in the muscle of SOD1(G93A) rats, specifically near intramuscular axons and NMJs. Interestingly, strong expression of activated glial markers, glial fibrillary acidic protein (GFAP) and nestin, was observed in the areas adjacent to NMJs. Finally, we determined whether ex vivo trophic factor delivery influences inflammation and terminal Schwann cell (TSC) response during ALS. We found that intramuscular transplantation of hMSC-GDNF tended to exhibit less inflammation and significantly maintained TSC association with NMJs. Understanding cellular responses near NMJs is important to identify suitable cellular and molecular targets for novel treatment of ALS and other neuromuscular diseases.

Indexed as

Amyotrophic Lateral SclerosisAnimalsAntigens, CDDisease Models, AnimalGlial Cell Line-Derived Neurotrophic FactorGlial Cell Line-Derived Neurotrophic Factor ReceptorsInflammationInterleukin-1betaMacrophagesMuscle, SkeletalNerve Tissue ProteinsNeurogliaNeuromuscular JunctionRatsRats, TransgenicReceptors, CholinergicAntigens, CDGfra1 protein, ratGlial Cell Line-Derived Neurotrophic FactorGlial Cell Line-Derived Neurotrophic Factor ReceptorsInterleukin-1betaNerve Tissue ProteinsReceptors, CholinergicS100 Calcium Binding Protein beta SubunitSOD1 G93A proteinSuperoxide DismutaseTumor Necrosis Factor-alphaAmyotrophic lateral sclerosis (ALS)Glial activationInflammationSkeletal muscleSOD1(G93A) rats

Identifiers

PMID26775178
PMCPMC4762214
OpenAlexW2234805249

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.